RxDoctor Payments Data

Stephanie McKenney Groff, DO

Family Medicine · Poolesville, MDNPI 1700346137

Payments from drug & device makers

$788in general payments, 2019–2025

Across 33 payments — averaging $23.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$198
  • GSK$171
  • Lilly USA, LLC$125
  • Pfizer$57
  • AstraZeneca$45
  • Optinose US, Inc.$40
  • plus $153 from 7 others

What the payments were for

  • Food & beverage$788100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$788 in reported general payments places this provider in the 60th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$195,602
Medicare patients
573
Services billed
4,690

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide43$60,535
EliquisApixaban41$54,851
OzempicSemaglutide28$47,137
JardianceEmpagliflozin22$32,755
CreonLipase/Protease/Amylase11$29,518
TrulicityDulaglutide14$27,401
JanuviaSitagliptin Phosphate19$24,736
FarxigaDapagliflozin Propanediol17$24,110
XareltoRivaroxaban15$23,426
LinzessLinaclotide13$14,289
Rosuvastatin Calcium235$7,636
Metoprolol Succinate154$4,332
Atorvastatin Calcium209$4,093
SynthroidLevothyroxine Sodium54$3,996
Pravastatin Sodium127$3,512

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$125$87,93657 claims
PfizerEliquis, Paxlovid$57$56,28055 claims
Novo NordiskOzempic$198$47,13728 claims
Boehringer IngelheimJardiance$21$32,75522 claims
AstraZenecaFarxiga$45$24,11017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Poolesville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →